The EU Health Technology Assessment (HTA) regulation, which will begin to apply from January 2025, will see companies further utilize historical data to demonstrate the clinical impact of their product, said Christian Schneider, of the pharmaceutical services provider, Cencora, and a former chair of the European Medicines Agency’s Committee for Advanced Therapies (CAT).
Why Historical Data Will Be Important Under The New EU HTA Regulation
The incoming EU Health Technology Assessment Regulation will see historical data move “more center stage” for advanced therapies, because directly comparing highly individualized therapies is often unfeasible, an advanced therapies expert says.
More from Health Technology Assessment
More from Rare Diseases
• By
Pharming has convinced NICE to reverse its rejection of its treatment for APDS by providing the health technology assessment institute with more data. It has also dropped the price it was asking for the drug, which has a list price of £352,000 per year per patient.
• By
A new Innovative Health Initiative project will see the German health technology appraisal (HTA) body, IQWiG, work towards ensuring evidence generated in clinical studies meets the needs of HTA bodies and regulators.
• By
Democrats are raising concerns that the continuing resolution intended to fund the government for the remainder of fiscal year 2025 gives Trump too much power, though it is unclear whether the FDA would be as impacted as other agencies.